Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

LCI-NEU-NOV-001: A Phase II Study of Optune in Combination with Bevacizumab (BEV) and Temozolomide (TMZ) in Patients with Newly Diagnosed Unresectable Glioblastoma (GBM)
Brief Description  
Primary Objective The primary objective of this phase II study is to assess the efficacy of a treatment regimen that involves the administration of temozolomide and bevacizumab with concurrent use of the medical device, NovoTTF?-100A System, by evaluating the percentage of newly diagnosed unresectable glioblastoma (GBM) patients who are alive at 12 months. Secondary Objective - Evaluate progression free survival (PFS) - Evaluate overall response rate (ORR) and disease control rate (DCR)
Who may be Eligible  
Please contact us for eligibility criteria.
Brain and Nervous System
Start Date  
IRB Number  
Principal Investigator  
Sumrall, Ashley Love
Contact Name  
Sylvia Rushing

For More Information, Contact  Sylvia  , Rushing
Phone:  980-442-2358 Fax:    
Email:  Sylvia.Rushing@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204